Wilson Sonsini Reps Fluidigm In $207M DVS Sciences Deal
Biotech tools company Fluidigm Corp. has signed a deal to buy DVS Sciences Inc. for $207.5 million, strengthening its portfolio in single-cell analysis technology, the company said Wednesday....To view the full article, register now.
Already a subscriber? Click here to view full article